A Multicenter Retrospective Case Review of Outcomes and Complications of S53P4 Bioactive Glass

Overview

Journal J Int Adv Otol

Publisher Aves

Specialty Otorhinolaryngology

Date 2021 Jun 8

PMID 34100748

Citations 4

Authors

Colin G Leonard

Sinead McNally

Mark Adams

Susie Hampton

Edward McNaboe

C Ekambar E Reddy

Neil A Bailie

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this multicenter retrospective case review was to assess the natural clinical course, efficacy, and safety of mastoid obliteration with S53P4 Bioactive Glass (bioactive glass).

Methods: Retrospective case note review in a regional Tertiary Referral Centre and District General Hospital. Patients undergoing mastoid cavity obliteration as part of primary or secondary procedure with bioactive glass between 2012 and 2018. Outcome measures were assessed from a prospectively collated database and case note review. Primary outcomes were the common morbidities of a mastoid cavity; dry or discharging ear (Merchant's scale), vertigo in cold air, and a watertight middle ear. Patients were also assessed for audiological outcomes and recidivism.

Results: Ninety patients were included. During the follow-up period, (mean, 22 months; range, 6-59 months) cholesteatoma recidivism was observed in 2% of ears (2 patients). An acceptably dry (Merchant Grade 0-1) ear was achieved in 91% of all ears (95% primary cases, 80% secondary cases). Delayed healing of the graft in the external ear canal retaining the S53P4BAG Bioactive Glass (BonAlive Ò (BonAlive Ò Biomaterials Ltd., Turku, Finland)) within the mastoid occurred in 13% (12 ears). However, in all cases, conservative management resulted in complete healing.

Conclusions: Bioactive glass provides a safe and effective means of mastoid obliteration. Complications including overlay graft failure and slow epithelialization, resulting in prolonged postoperative discharge (up to 2 months) and dehiscence into the external ear canal, do not preclude full recovery and may be successfully managed conservatively.

Citing Articles

Heterologous Materials Are Really Better than Autologous in Tympanoplasty Mastoid Obliteration? A Systematic Review with Meta-Analysis.

Viberti F, Monciatti G, Donniacuo A, Ferretti F, Salerni L, De Vito A J Int Adv Otol. 2024; 20(5):439-449.

PMID: 39390967 PMC: 11562477. DOI: 10.5152/iao.2024.241262.

Efficacy of S53P4 Bioactive Glass for the Secondary Obliteration of Chronically Discharging Radical Cavities.

Kroon V, Mes S, Borggreven P, van de Langenberg R, Colnot D, Quak J OTO Open. 2023; 7(4):e96.

PMID: 38034064 PMC: 10685330. DOI: 10.1002/oto2.96.

Mastoid obliteration and external auditory canal reconstruction using 3D printed bioactive glass S53P4 /polycaprolactone scaffold loaded with bone morphogenetic protein-2: A simulation clinical study in rabbits.

Yu F, Fan X, Wu H, Ou Y, Zhao X, Chen T Regen Ther. 2022; 21:469-476.

PMID: 36313396 PMC: 9588957. DOI: 10.1016/j.reth.2022.09.010.

Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?.

Cals F, van der Toom H, Metselaar R, van Linge A, van der Schroeff M, Pauw R J Otol. 2022; 17(1):25-30.

PMID: 35140756 PMC: 8811380. DOI: 10.1016/j.joto.2021.10.001.

References

Yung M, James A, Merkus P, Philips J, Black B, Tono T . International Otology Outcome Group and the International Consensus on the Categorization of Tympanomastoid Surgery. J Int Adv Otol. 2018; 14(2):216-226. PMC: 6354466. DOI: 10.5152/iao.2018.5553. View

Yung M, Bennett A . Use of mastoid obliteration techniques in cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2013; 21(5):455-60. DOI: 10.1097/MOO.0b013e3283646521. View

Skoulakis C, Koltsidopoulos P, Iyer A, Kontorinis G . Mastoid Obliteration with Synthetic Materials: A Review of the Literature. J Int Adv Otol. 2019; 15(3):400-404. PMC: 6937173. DOI: 10.5152/iao.2019.7038. View

Munukka E, Lepparanta O, Korkeamaki M, Vaahtio M, Peltola T, Zhang D . Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. J Mater Sci Mater Med. 2007; 19(1):27-32. DOI: 10.1007/s10856-007-3143-1. View

Silvola J . Mastoidectomy cavity obliteration with bioactive glass: a pilot study. Otolaryngol Head Neck Surg. 2012; 147(1):119-26. DOI: 10.1177/0194599812438168. View

Bernardeschi D, Nguyen Y, Russo F, Mosnier I, Ferrary E, Sterkers O . Cutaneous and Labyrinthine Tolerance of Bioactive Glass S53P4 in Mastoid and Epitympanic Obliteration Surgery: Prospective Clinical Study. Biomed Res Int. 2015; 2015:242319. PMC: 4609330. DOI: 10.1155/2015/242319. View

Kurien G, Greeff K, Gomaa N, Ho A . Mastoidectomy and mastoid obliteration with autologous bone graft: a quality of life study. J Otolaryngol Head Neck Surg. 2013; 42:49. PMC: 3849804. DOI: 10.1186/1916-0216-42-49. View

Bernardeschi D, Pyatigorskaya N, Russo F, De Seta D, Corallo G, Ferrary E . Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study. Clin Otolaryngol. 2016; 42(2):387-396. DOI: 10.1111/coa.12748. View

Lee H, Lim H, Cho M, Yang S, Park K, Park H . Clinical Significance of β-Tricalcium Phosphate and Polyphosphate for Mastoid Cavity Obliteration during Middle Ear Surgery: Human and Animal Study. Clin Exp Otorhinolaryngol. 2013; 6(3):127-34. PMC: 3781224. DOI: 10.3342/ceo.2013.6.3.127. View

10.

Trinidade A, Skingsley A, Yung M . Pediatric cholesteatoma surgery using a single-staged canal wall down approach: results of a 5-year longitudinal study. Otol Neurotol. 2014; 36(1):82-5. DOI: 10.1097/MAO.0000000000000598. View

11.

Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romano C . Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains. Future Microbiol. 2015; 10(8):1293-9. DOI: 10.2217/FMB.15.57. View

12.

Valimaki V, Aro H . Molecular basis for action of bioactive glasses as bone graft substitute. Scand J Surg. 2006; 95(2):95-102. DOI: 10.1177/145749690609500204. View

13.

Saleh H, Mills R . Classification and staging of cholesteatoma. Clin Otolaryngol Allied Sci. 1999; 24(4):355-9. DOI: 10.1046/j.1365-2273.1999.00272.x. View

14.

Lepparanta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M . Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. J Mater Sci Mater Med. 2007; 19(2):547-51. DOI: 10.1007/s10856-007-3018-5. View

15.

Merchant S, Wang P, Jang C, Glynn R, Rauch S, McKenna M . Efficacy of tympanomastoid surgery for control of infection in active chronic otitis media. Laryngoscope. 1997; 107(7):872-7. DOI: 10.1097/00005537-199707000-00007. View